Literature DB >> 26823776

PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.

Yu Xu1, Qingcai Yue2, Hong Wei3, Guiju Pan1.   

Abstract

PRAME is a germinal tissue-specific gene that is expressed at high levels in haematological malignancies, but the physiological functions of PRAME in leukemia cells are unknown. It has reported that PRAME was found to be predominantly expressed in acute leukemias and high PRAME expression is correlated with a favorable prognosis in childhood acute leukemias, which suggested that PRAME could be involved in the regulation of cell death or apoptosis. In the present study, we tested a hypothesis that the PRAME gene plays a role in the regulation of apoptosis and proliferation of leukemia cells. We observed that KG-1 cells transient overexpressing the PRAME gene (when transfected with pcDNA3.1-PRAME plasmid) significantly induces apoptosis and decreases proliferation in vitro, and repression of PRAME expression by a short interfering RNA exhibited a increased proliferation in K562 cells in vitro and increases tumorigenicity of K562 leukemic cells in nude mice. Our results suggest that the leukemias expressing high levels of PRAME has favorable prognosis. PRAME may be as an attractive target for potential immunotherapy for acute leukemic.

Entities:  

Keywords:  Acute leukemias; PRAME; apoptosis; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26823776      PMCID: PMC4713562     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

Authors:  H Ikeda; B Lethé; F Lehmann; N van Baren; J F Baurain; C de Smet; H Chambost; M Vitale; A Moretta; T Boon; P G Coulie
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

2.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Authors:  Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

3.  PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.

Authors:  C A Abdelmalak; R S Yahya; D M Elghannam; A E El-Khadragy; H M Abd El Messih
Journal:  Clin Lab       Date:  2014       Impact factor: 1.138

4.  Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.

Authors:  Norina Tanaka; Yan-Hua Wang; Masayuki Shiseki; Minoko Takanashi; Toshiko Motoji
Journal:  Leuk Res       Date:  2011-05-07       Impact factor: 3.156

5.  The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.

Authors:  André Oberthuer; Barbara Hero; Rüdiger Spitz; Frank Berthold; Matthias Fischer
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

6.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Authors:  Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo
Journal:  Blood       Date:  2008-11-04       Impact factor: 22.113

7.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Authors:  Vivian G Oehler; Katherine A Guthrie; Carrie L Cummings; Kathleen Sabo; Brent L Wood; Ted Gooley; Taimei Yang; Mirjam T Epping; Yaping Shou; Era Pogosova-Agadjanyan; Paula Ladne; Derek L Stirewalt; Janis L Abkowitz; Jerald P Radich
Journal:  Blood       Date:  2009-07-22       Impact factor: 22.113

8.  Gene expression changes associated with progression and response in chronic myeloid leukemia.

Authors:  Jerald P Radich; Hongyue Dai; Mao Mao; Vivian Oehler; Jan Schelter; Brian Druker; Charles Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen Friend; Peter S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.

Authors:  N van Baren; H Chambost; A Ferrant; L Michaux; H Ikeda; I Millard; D Olive; T Boon; P G Coulie
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

10.  PRAME Gene Expression in Acute Leukemia and Its Clinical Significance.

Authors:  Kai Ding; Xiao-Ming Wang; Rong Fu; Er-Bao Ruan; Hui Liu; Zong-Hong Shao
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

View more
  3 in total

1.  Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism.

Authors:  Meijing Wu; Jason Miska; Ting Xiao; Peng Zhang; J Robert Kane; Irina V Balyasnikova; James P Chandler; Craig M Horbinski; Maciej S Lesniak
Journal:  J Neurooncol       Date:  2019-01-31       Impact factor: 4.130

2.  PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Authors:  Wa Zhang; Carter J Barger; Kevin H Eng; David Klinkebiel; Petra A Link; Angela Omilian; Wiam Bshara; Kunle Odunsi; Adam R Karpf
Journal:  Oncotarget       Date:  2016-07-19

Review 3.  The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.

Authors:  Yichi Xu; Ruanmin Zou; Jing Wang; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Cell Prolif       Date:  2020-02-05       Impact factor: 6.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.